Telescope still effective at two years

Article

The Implantable Miniature Telescope (IMT) from VisionCare for end-stage age-related macular degeneration (AMD) maintains best-corrected visual acuity (BCVA) improvements to two years, according to results published in the November edition of the American Journal of Ophthalmology.

VisionCare's Implantable Miniature Telescope (IMT) for end-stage age-related macular degeneration (AMD) maintains best-corrected visual acuity (BCVA) improvements to two years, according to results published in the November edition of the American Journal of Ophthalmology.

Henry L. Hudson of the Retina Centers, PC, Tucson, Arizona (US) and colleagues implanted the IMT in end-stage AMD patients with BCVA of 20/80 to 20/800 (n=188) in a multicentre, open-label, prospective Phase II/III trial, which was designed to assess safety and efficacy. Data from 92.6% of implanted eyes were available.

At 24 months, 59.5% of eyes (n=103) improved BCVA by ≥3 lines. In patients implanted with the 3X magnifying lens, mean BCVA improvement from baseline was 3.6 lines; in patients implanted with the 2.2X magnifying lens, this improvement was 2.8 lines. BCVA decreased by ≥3 lines in 0.6% of implanted eyes. At the 24-month follow-up visit, endothelial cell loss had increased by 2.4% to 27% from the 12-month follow-up, although endothelial cell dysfunction (ECD) was stable. The most frequently observed adverse event was inflammatory deposits.

The investigators concluded that the benefits of the IMT were maintained at two years, with - in comparison with the BCVA improvements - only minor surgical risks. The device is currently CE marked and is awaiting FDA approval.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.